CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 440 enrolled
Drug / intervention
AGN-199201 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02131636
NCT02131636Phase 3Completed
CompareCT.gov

Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea

Allergan·interventional·Posted May 6, 2014·Updated Nov 18, 2019

In Brief

A Phase 3 clinical trial evaluating AGN-199201 and Vehicle to AGN-199201 for Erythema and Rosacea. Completed, enrolled 440 participants across 1 site.

Detailed Summary

This study will evaluate the safety and efficacy of AGN-199201 once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsErythema, Rosacea
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 6, 2014
Enrollment StartMay 1, 2014
Primary CompletionNov 1, 2014
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 12.2 years ago

Interventions

AGN-199201drug

AGN-199201 applied to the face once daily for 29 days.

Vehicle to AGN-199201drug

Vehicle to AGN-199201 applied to the face once daily for 29 days.